Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GRI Bio, Inc.VLON · Entity 8336 | Director | February 23, 2022 | March 09, 2022 |
| KINETA, INC./DEPTI · Entity 77778 | Director · President and CEO | March 02, 2020 | March 04, 2020 |
| MACROGENICS INCMGNX · Entity 6104 | Director | May 18, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GRI Bio, Inc.
Report date February 23, 2022 · Filed March 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.67 · Expires 2032-02-23 | Direct | 15,000 |
Reported balance
After 2022-02-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-23 · Grant · Acquired 15,000 · Balance 15,000 F1: Reported late due to administrative error. F2: This stock options vests in 24 equal monthly installments such that the stock options shall be fully vested as of the second annual anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reported late due to administrative error.
F2: This stock options vests in 24 equal monthly installments such that the stock options shall be fully vested as of the second annual anniversary of the date of grant.
KINETA, INC./DE
Report date March 02, 2020 · Filed March 04, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.57 · Expires 2030-03-02 | Direct | 406,800 |
Reported balance
After 2020-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-03-02 · Grant · Acquired 406,800 · Balance 406,800 F1: These securities shall vest and become exercisable in a series of installments, with the first installment to become exercisable for 25% of the underlying common stock on February 4, 2021, and thereafter vesting and becoming exercisable in 12 quarterly installments as nearly equal as practicable (as determined by the Issuer in its reasonable discretion), until such stock option becomes fully exercisable on February 4, 2024, provided that the Reporting Person remains an employee of Issuer at all times during the applicable vesting period of such securities. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities shall vest and become exercisable in a series of installments, with the first installment to become exercisable for 25% of the underlying common stock on February 4, 2021, and thereafter vesting and becoming exercisable in 12 quarterly installments as nearly equal as practicable (as determined by the Issuer in its reasonable discretion), until such stock option becomes fully exercisable on February 4, 2024, provided that the Reporting Person remains an employee of Issuer at all times during the applicable vesting period of such securities.
MACROGENICS INC
Report date May 18, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,750 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Exercise / conversion · Acquired 3,750 · Balance 14,750 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.52 · Expires 2036-05-19 | Direct | 22,000 |
Reported balance
After 2026-05-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-19 · Grant · Acquired 22,000 · Balance 22,000 F2: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,750 |
Reported balance
After 2026-05-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-19 · Grant · Acquired 3,750 · Balance 3,750 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-18 · Exercise / conversion · Disposed 3,750 · Balance 0 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F4: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
F2: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.
F3: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier
F4: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Apexigen, Inc.
Report date August 23, 2023 · Filed August 25, 2023
Section 16 reporting ended · disclosed 2023-08-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 · Expires 2032-09-29 | Direct | 0 |
Reported balance
After 2023-08-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-23 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023, by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023, by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 19, 2026 Filed May 20, 2026 20:13 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001534200-26-000003 · wk-form4_1779308021.xml · derivative · entry 3 Chhabra Meenu · CIK 0001534200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier F3 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier Read SEC document |
| May 19, 2026 Filed May 20, 2026 20:13 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001534200-26-000003 · wk-form4_1779308021.xml · derivative · entry 2 Chhabra Meenu · CIK 0001534200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2036-05-19 F2 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:13 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001534200-26-000003 · wk-form4_1779308021.xml · derivative · entry 4 Chhabra Meenu · CIK 0001534200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026. F4 · derivative.expiration_date: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:13 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001534200-26-000003 · wk-form4_1779308021.xml · nonDerivative · entry 1 Chhabra Meenu · CIK 0001534200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 21, 2025 Filed May 22, 2025 20:01 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 49,213 | $1.27 Strike: $1.49 | $62,500.51 |
DisclosureSEC source: 0001125345-25-000077 · wk-form4_1747944096.xml · derivative · entry 5 Chhabra Meenu · CIK 0001534200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,213 Underlying: Common Stock · 49,213 shares Expires 2035-05-21 F4 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. F5 · derivative.underlying_shares: At the election of the filing person, the option grant is issued in lieu of direct cash compensation of such person's annual retainer through the Company's non-employee director compensation program and will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant. Read SEC document |
| May 21, 2025 Filed May 22, 2025 20:01 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001125345-25-000077 · wk-form4_1747944096.xml · derivative · entry 4 Chhabra Meenu · CIK 0001534200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2035-05-21 F4 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| May 21, 2025 Filed May 22, 2025 20:01 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-25-000077 · wk-form4_1747944096.xml · derivative · entry 3 Chhabra Meenu · CIK 0001534200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier F3 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:01 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 6,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-25-000077 · wk-form4_1747944096.xml · derivative · entry 2 Chhabra Meenu · CIK 0001534200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested on May 20, 2025, which was one day prior to the Issuer's 2025 Annual Meeting of Stockholders held on May 21, 2025. F2 · derivative.expiration_date: The RSUs vested on May 20, 2025, which was one day prior to the Issuer's 2025 Annual Meeting of Stockholders held on May 21, 2025. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:01 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 6,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001125345-25-000077 · wk-form4_1747944096.xml · nonDerivative · entry 1 Chhabra Meenu · CIK 0001534200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 21, 2024 Filed May 23, 2024 21:18 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 17,077 | $3.66 Strike: $4.26 | $62,501.82 |
DisclosureSEC source: 0001125345-24-000133 · wk-form4_1716499080.xml · derivative · entry 3 Chhabra Meenu · CIK 0001534200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,577 Underlying: Common Stock · 17,077 shares Expires 2034-05-21 F3 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. F4 · derivative.underlying_shares: At the election of the filing person, the option grant is issued in lieu of direct cash compensation of such person's annual retainer through the Company's non-employee director compensation program and will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant. Read SEC document |
| May 21, 2024 Filed May 23, 2024 21:18 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $4.26 | $0.00 |
DisclosureSEC source: 0001125345-24-000133 · wk-form4_1716499080.xml · derivative · entry 2 Chhabra Meenu · CIK 0001534200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2034-05-21 F3 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| May 21, 2024 Filed May 23, 2024 21:18 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 6,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000133 · wk-form4_1716499080.xml · derivative · entry 1 Chhabra Meenu · CIK 0001534200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier F2 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:33 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 4,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000103 · wk-form4_1716409983.xml · derivative · entry 2 Chhabra Meenu · CIK 0001534200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock unit (RSU) grant was approved by the Board of Directors on May 31, 2023. Each RSU represents a contingent right to receive one share of the Issuer Common Stock. F2 · derivative.exercise_date: The RSUs vested on May 20, 2024, which was one day prior to the Issuer's 2024 Annual Meeting of Stockholders held on May 21, 2024. F2 · derivative.expiration_date: The RSUs vested on May 20, 2024, which was one day prior to the Issuer's 2024 Annual Meeting of Stockholders held on May 21, 2024. Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:33 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000103 · wk-form4_1716409983.xml · nonDerivative · entry 1 Chhabra Meenu · CIK 0001534200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock unit (RSU) grant was approved by the Board of Directors on May 31, 2023. Each RSU represents a contingent right to receive one share of the Issuer Common Stock. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 19:31 UTC | Apexigen, Inc. APGN · Entity 110214 | Disposition to issuerStock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $2.65 | Not disclosed |
DisclosureSEC source: 0001209191-23-047448 · doc4.xml · derivative · entry 1 Chhabra Meenu · CIK 0001534200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2032-09-29 F1 · price: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023, by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. F1 · derivative.exercise_date: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023, by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:50 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $4.67 | $0.00 |
DisclosureSEC source: 0001125345-23-000093 · wk-form4_1685739001.xml · derivative · entry 3 Chhabra Meenu · CIK 0001534200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2033-05-31 F3 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:50 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 15,759 | $0.00 Strike: $4.67 | $0.00 |
DisclosureSEC source: 0001125345-23-000093 · wk-form4_1685739001.xml · derivative · entry 2 Chhabra Meenu · CIK 0001534200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,759 Underlying: Common Stock · 15,759 shares Expires 2033-05-31 F3 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. F4 · derivative.underlying_shares: At the election of the filing person, the option grant is issued in lieu of direct cash compensation of such person's annual retainer through the Company's non-employee director compensation program and will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:50 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 4,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-23-000093 · wk-form4_1685739001.xml · derivative · entry 1 Chhabra Meenu · CIK 0001534200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer?s Common Stock. The RSU grant was approved by the Issuer?s Board of Directors on May 31, 2023 and will be effective as of the date the Issuer has an effective Registration Statement on Form S-8 registering the shares available for issuance under the 2023 Equity Incentive Plan. F2 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier F2 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:42 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001125345-23-000019 · wf-form4_167295491283833.xml · derivative · entry 1 Chhabra Meenu · CIK 0001534200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2033-01-03 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/36th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 18:21 UTC | Apexigen, Inc. APGN · Entity 110214 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001209191-22-051945 · doc4.xml · derivative · entry 1 Chhabra Meenu · CIK 0001534200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-09-29 F1 · derivative.exercise_date: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Read SEC document |
| February 23, 2022 Filed Mar 9, 2022 22:02 UTC | GRI Bio, Inc. VLON · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $7.67 Strike: $7.67 | $115,050.00 |
DisclosureSEC source: 0001824293-22-000015 · wf-form4_164686330942029.xml · derivative · entry 1 Chhabra Meenu · CIK 0001534200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-02-23 F1 · date: Reported late due to administrative error. F2 · derivative.exercise_date: This stock options vests in 24 equal monthly installments such that the stock options shall be fully vested as of the second annual anniversary of the date of grant. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 17:04 UTC | KINETA, INC./DE PTI · Entity 77778 | GrantEmployee Stock Option (right to buy) · Derivative | 406,800 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001209191-20-016213 · doc4.xml · derivative · entry 1 Chhabra Meenu · CIK 0001534200 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,800 Underlying: Common Stock · 406,800 shares Expires 2030-03-02 F1 · derivative.exercise_date: These securities shall vest and become exercisable in a series of installments, with the first installment to become exercisable for 25% of the underlying common stock on February 4, 2021, and thereafter vesting and becoming exercisable in 12 quarterly installments as nearly equal as practicable (as determined by the Issuer in its reasonable discretion), until such stock option becomes fully exercisable on February 4, 2024, provided that the Reporting Person remains an employee of Issuer at all times during the applicable vesting period of such securities. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 16:35 UTC | KINETA, INC./DE PTI · Entity 77778 | GrantStock Option (Right to Buy) · Derivative | 367,700 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001209191-19-016537 · doc4.xml · derivative · entry 1 Chhabra Meenu · CIK 0001534200 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,700 Underlying: Common Stock · 367,700 shares Expires 2029-03-01 F1 · derivative.exercise_date: These securities shall vest and become exercisable in a series of installments, with the first installment to become exercisable for 25% of the underlying common stock on February 8, 2020, and thereafter vesting and becoming exercisable in 12 quarterly installments as nearly equal as practicable (as determined by the Issuer in its reasonable discretion), until such stock option becomes fully exercisable on February 8, 2023, provided that the Reporting Person remains an employee of Issuer at all times during the applicable vesting period of such securities. Read SEC document |
| February 04, 2019 Filed Feb 5, 2019 19:57 UTC | KINETA, INC./DE PTI · Entity 77778 | SaleCommon Stock | 16,478 | $2.99 | $49,305.47 |
DisclosureSEC source: 0001209191-19-007568 · doc4.xml · nonDerivative · entry 2 Chhabra Meenu · CIK 0001534200 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,615 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and were made in order to pay the tax liability arising from the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.96 to $3.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 19:57 UTC | KINETA, INC./DE PTI · Entity 77778 | Exercise / conversionRestricted Stock Units · Derivative | 46,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-007568 · doc4.xml · derivative · entry 3 Chhabra Meenu · CIK 0001534200 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PTI common stock. F4 · derivative.exercise_date: The restricted stock units vested in full on February 1, 2019. F4 · derivative.expiration_date: The restricted stock units vested in full on February 1, 2019. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 19:57 UTC | KINETA, INC./DE PTI · Entity 77778 | Exercise / conversionCommon Stock | 46,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-007568 · doc4.xml · nonDerivative · entry 1 Chhabra Meenu · CIK 0001534200 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,093 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of PTI common stock. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 17:31 UTC | KINETA, INC./DE PTI · Entity 77778 | GrantEmployee Stock Option (Right to Buy) · Derivative | 240,800 | $0.00 Strike: $3.11 | $0.00 |
DisclosureSEC source: 0001209191-18-016684 · doc4.xml · derivative · entry 1 Chhabra Meenu · CIK 0001534200 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,800 Underlying: Common Stock · 240,800 shares Expires 2028-03-01 F1 · derivative.exercise_date: These securities shall vest and become exercisable in a series of installments, with the first installment to become exercisable for 25% of the underlying common stock on February 1, 2019, and thereafter vesting and becoming exercisable in 12 quarterly installments as nearly equal as practicable (as determined by the Issuer in its reasonable discretion), until such stock option becomes fully exercisable on February 1, 2022, provided that the Reporting Person remains an employee of Issuer at all times during the applicable vesting period of such securities. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 17:21 UTC | KINETA, INC./DE PTI · Entity 77778 | GrantRestricted Stock Units · Derivative | 46,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-007592 · doc4.xml · derivative · entry 1 Chhabra Meenu · CIK 0001534200 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,875 Underlying: Common Stock · 46,875 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PTI common stock. F2 · derivative.exercise_date: The restricted stock units shall vest in full on February 1, 2019. F2 · derivative.expiration_date: The restricted stock units shall vest in full on February 1, 2019. Read SEC document |
| December 18, 2017 Filed Dec 19, 2017 08:47 UTC | KINETA, INC./DE PTI · Entity 77778 | PurchaseCommon Stock | 40,000 | $5.00 | $200,000.00 |
DisclosureSEC source: 0001209191-17-066247 · doc4.xml · nonDerivative · entry 1 Chhabra Meenu · CIK 0001534200 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,218 Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 16:33 UTC | KINETA, INC./DE PTI · Entity 77778 | GrantEmployee Stock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $7.56 | $0.00 |
DisclosureSEC source: 0001209191-17-025669 · doc4.xml · derivative · entry 1 Chhabra Meenu · CIK 0001534200 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2027-04-03 F1 · derivative.exercise_date: These securities shall vest and become exercisable in a series of installments, with the first installment to become exercisable for 25% of the underlying common stock on March 8, 2018, and thereafter vesting and becoming exercisable in 12 quarterly installments as nearly equal as practicable (as determined by the Issuer in its reasonable discretion), until such stock option becomes fully exercisable on March 8, 2021, provided that the Reporting Person remains an employee of Issuer at all times during the applicable vesting period of such securities. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.